Clinical Research Directory
Browse clinical research sites, groups, and studies.
Finding Links Between Hot flASHes and CardioVascular Disease
Sponsor: Massachusetts General Hospital
Summary
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Key Details
Gender
FEMALE
Age Range
40 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-04
Completion Date
2030-10
Last Updated
2026-02-12
Healthy Volunteers
No
Conditions
Interventions
elinzanetant - reference formulation
elinzanetant 120 mg daily x 12 weeks
placebo
placebo daily x 12 weeks
Locations (2)
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States